The Th17 pathway as a therapeutic target in rheumatoid arthritis and other autoimmune and inflammatory disorders. (Q38101877)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23620106%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

title

The Th17 pathway as a therapeutic target in rheumatoid arthritis and other autoimmune and inflammatory disorders (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23620106%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

Annemarie van Nieuwenhuijze

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23620106%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Marije Koenders

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23620106%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

author name string

Debbie M Roeleveld

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23620106%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Wim B van den Berg

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23620106%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

language of work or name

1 reference

1 October 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23620106%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23620106%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23620106%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23620106%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

page(s)

439-452

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23620106%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s40259-013-0035-4

29 February 2020

exact match

0 references

cites work

Interleukin-17 family and IL-17 receptors

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Functional specialization of interleukin-17 family members

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Mast cells express IL-17A in rheumatoid arthritis synovium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Interleukin-17 and type 17 helper T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Infliximab reduces the frequency of interleukin 17-producing cells and the amounts of interleukin 17 in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Estrogen deficiency induces the differentiation of IL-17 secreting Th17 cells: a new candidate in the pathogenesis of osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Interleukin 17 synergises with tumour necrosis factor alpha to induce cartilage destruction in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Interleukin-21 promotes osteoclastogenesis in humans with rheumatoid arthritis and in mice with collagen-induced arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

In vivo and in vitro roles of IL-21 in inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

A positive feedback loop of IL-21 signaling provoked by homeostatic CD4+CD25- T cell expansion is essential for the development of arthritis in autoimmune K/BxN mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Proinflammatory role of the Th17 cytokine interleukin-22 in collagen-induced arthritis in C57BL/6 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Development, cytokine profile and function of human interleukin 17-producing helper T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

IL-21 and TGF-beta are required for differentiation of human T(H)17 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Autocrine transforming growth factor-β1 promotes in vivo Th17 cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Signals mediated by transforming growth factor-beta initiate autoimmune encephalomyelitis, but chronic inflammation is needed to sustain disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Smad2 positively regulates the generation of Th17 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

TGF-beta promotes Th17 cell development through inhibition of SOCS3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Regulating human Th17 cells via differential expression of IL-1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Transforming growth factor-beta induces development of the T(H)17 lineage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Essential autocrine regulation by IL-21 in the generation of inflammatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Fate mapping of IL-17-producing T cells in inflammatory responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

IFN-γ and IL-12 synergize to convert in vivo generated Th17 into Th1/Th17 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

The pathogenesis of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Current understanding of rheumatoid arthritis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Increased IL-17 production by peripheral T helper cells after tumour necrosis factor blockade in rheumatoid arthritis is accompanied by inhibition of migration-associated chemokine receptor expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Low dose CP-690,550 (tofacitinib), a pan-JAK inhibitor, accelerates the onset of experimental autoimmune encephalomyelitis by potentiating Th17 differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing RORγt activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Structural Basis of Digoxin That Antagonizes ROR t Receptor Activity and Suppresses Th17 Cell Differentiation and Interleukin (IL)-17 Production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Interleukin-23: a key cytokine in inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Cytokines in the pathogenesis of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

High amounts of circulating interleukin (IL)-6 in the form of monomeric immune complexes during anti-IL-6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Targeting the TGF beta signaling network in human neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Antibody targeting of TGF-β in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Molecular pathways: targeting the TGF-β pathway for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Vitamin D analog calcipotriol suppresses the Th17 cytokine-induced proinflammatory S100 "alarmins" psoriasin (S100A7) and koebnerisin (S100A15) in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

IL-17 mRNA in sputum of asthmatic patients: linking T cell driven inflammation and granulocytic influx?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Airway remodeling-associated mediators in moderate to severe asthma: effect of steroids on TGF-beta, IL-11, IL-17, and type I and type III collagen expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Th17 immunity in patients with allergic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

The overexpression of heparin-binding epidermal growth factor is responsible for Th17-induced airway remodeling in an experimental asthma model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Development of allergen-induced airway inflammation in the absence of T-bet regulation is dependent on IL-17.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

IL-23/IL-17 immunity as a hallmark of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Increased expression of interleukin 17 in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Late Crohn's disease patients present an increase in peripheral Th17 cells and cytokine production compared with early patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Interleukin 17 gene and protein expression are increased in patients with ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Porphyria cutanea tarda as a predictor of poor response to interferon alfa therapy in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Differential effect of IL-27 on developing versus committed Th17 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Treatment with IL-27 attenuates experimental colitis through the suppression of the development of IL-17-producing T helper cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Critical role of Th17 cells in development of autoimmune hemolytic anemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Patients with cystic fibrosis have inducible IL-17+IL-22+ memory cells in lung draining lymph nodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

IL-17-producing CD4-CD8- T cells are expanded in the peripheral blood, infiltrate salivary glands and are resistant to corticosteroids in patients with primary Sjogren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Both IFN-γ and IL-17 are required for the development of severe autoimmune gastritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

IL-17 mediated inflammation promotes tumor growth and progression in the skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Increased serum interleukin-17 in Graves' ophthalmopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Neutralization of the IL-17 axis diminishes neutrophil invasion and protects from ischemic stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Increased IL-1beta, IL-8, and IL-17 mRNA expression in blood mononuclear cells observed in a prospective ischemic stroke study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Pivotal role of cerebral interleukin-17-producing gammadeltaT cells in the delayed phase of ischemic brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

The macrophage mannose receptor induces IL-17 in response to Candida albicans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Development of a high-throughput cell-based assay for identification of IL-17 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Tumor necrosis factor-interleukin-17 interplay induces S100A8, interleukin-1β, and matrix metalloproteinases, and drives irreversible cartilage destruction in murine arthritis: Rationale for combination treatment during arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Anti IL-17A therapy inhibits bone loss in TNF-α-mediated murine arthritis by modulation of the T-cell balance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Increased expression of interleukin-22 by synovial Th17 cells during late stages of murine experimental arthritis is controlled by interleukin-1 and enhances bone degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

T cell lessons from the rheumatoid arthritis synovium SCID mouse model: CD3-rich synovium lacks response to CTLA-4ig but is successfully treated by interleukin-17 neutralization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4

The anti-CD20 antibody rituximab reduces the Th17 cell response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0035-4